JZY3221 is an androgen receptor ( AR ) inhibitor. JZY3221 binds to the AR ligand-binding domain to inhibit AR function. JZY3221 constitutes the AR inhibitory moiety of DALTAC JZY3032. JZY3221 is applicable to research related to prostate cancer [1].
In Vitro, JZY3221 exhibits only limited cell growth inhibitory activity in AR-positive 22Rv1 prostate cancer cells[1]. JZY3221 directly binds to purified AR protein[1].
References:
[1]. Luo J, et al. Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer. bioRxiv [Preprint]. 2026 Apr 28:2026.04.24.720638.
In Vitro, JZY3221 exhibits only limited cell growth inhibitory activity in AR-positive 22Rv1 prostate cancer cells[1]. JZY3221 directly binds to purified AR protein[1].
References:
[1]. Luo J, et al. Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer. bioRxiv [Preprint]. 2026 Apr 28:2026.04.24.720638.
















